ArticleJournal of maxillofacial and oral surgery2019
A Six-Gene-Based Prognostic Model Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients.
Article in Journal of maxillofacial and oral surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveHead and neck cancer is a malignant tumor that begins in the head and neck region, and has the sixth highest incidence worldwide. Previous studies have indicated several prognostic markers for head and neck squamous cell carcinoma (HNSCC), but due to poor accuracy and sensitivity of these clinical characteristic markers attention has been gradually switched to molecular biomarkers. This study aimed to sort out the mRNAs correlated with patient survival time to establish an mRNA combination prognostic biomarker model for HNSCC patient risk stratification, providing optimal therapeutic regimens and improving patient prognosis.
methodsClinical data and transcriptome sequencing data of HNSCC were retrieved from TCGA database and were allocated into training and validation datasets. The prognostic model was established using the mRNAs, which were sorted out from training dataset by a significant correlation with survival time. Eventually, the prediction property of the model was evaluated by Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curve.
resultsAn optimal prognostic model by the combination of six mRNAs was established. Kaplan-Meier survival analysis revealed effective risk stratification by this model for patients in the two datasets. The area under ROC curve (AUC) was > 0.65 for training and validation datasets, indicating good sensitivity and specificity of this model. Moreover, prominent superiority of this model to investigate prognostic biomarkers was demonstrated.
conclusionOur model provided effective prognostication in terms of death risk stratification and evaluation in HNSCC patients. Combination of this prognostic model with current treatment measures is expected to greatly improve the patients' prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.